Bbva Compass Bancshares Inc. Lowers Stake in Pfizer Inc. (NYSE:PFE)

Bbva Compass Bancshares Inc. reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.2% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 385,894 shares of the biopharmaceutical company’s stock after selling 25,461 shares during the period. Pfizer accounts for 0.9% of Bbva Compass Bancshares Inc.’s investment portfolio, making the stock its 22nd biggest holding. Bbva Compass Bancshares Inc.’s holdings in Pfizer were worth $13,776,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the stock. Shine Investment Advisory Services Inc. acquired a new position in Pfizer during the 2nd quarter worth $102,000. Mckinley Capital Management LLC Delaware acquired a new position in Pfizer during the 2nd quarter worth $103,000. D. Scott Neal Inc. lifted its position in Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 504 shares during the last quarter. Herndon Capital Management LLC acquired a new position in Pfizer during the 2nd quarter worth $120,000. Finally, Private Vista LLC raised its position in shares of Pfizer by 2,277.3% during the second quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 190,933 shares during the last quarter. 69.75% of the stock is owned by institutional investors and hedge funds.

Shares of Pfizer Inc. (NYSE PFE) opened at $36.60 on Wednesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. The firm has a market cap of $218,160.00, a PE ratio of 22.45, a price-to-earnings-growth ratio of 2.44 and a beta of 1.01. Pfizer Inc. has a 52 week low of $30.90 and a 52 week high of $37.35.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. During the same period in the prior year, the firm earned $0.61 earnings per share. Pfizer’s revenue was up .9% compared to the same quarter last year. sell-side analysts predict that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be paid a dividend of $0.34 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a dividend yield of 3.72%. The ex-dividend date is Thursday, February 1st. Pfizer’s dividend payout ratio is 78.53%.

Pfizer announced that its board has authorized a stock buyback program on Monday, December 18th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

A number of research analysts have recently commented on PFE shares. Nord/LB reaffirmed a “neutral” rating on shares of Pfizer in a research report on Wednesday, December 27th. Deutsche Bank set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. Goldman Sachs Group set a $36.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research report on Wednesday, November 1st. BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Friday, December 15th. Finally, Jefferies Group set a $39.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research report on Wednesday, November 1st. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $38.89.

In related news, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the transaction, the insider now directly owns 117,432 shares in the company, valued at $4,145,349.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the transaction, the executive vice president now owns 46,963 shares in the company, valued at $1,740,918.41. The disclosure for this sale can be found here. Insiders have sold 29,450 shares of company stock worth $1,065,220 over the last three months. 0.06% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “Bbva Compass Bancshares Inc. Lowers Stake in Pfizer Inc. (NYSE:PFE)” was posted by BBNS and is the sole property of of BBNS. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://baseballnewssource.com/markets/pfizer-inc-pfe-shares-sold-by-bbva-compass-bancshares-inc/1822605.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.